Conventional and biological therapy for inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Crohn's disease and ulcerative colitis are chronic, incurable inflammatory bowel diseases primarily affecting young adults in developed nations.
• Current treatments include aminosalicylates, corticosteroids, immunosuppressants, antibiotics, and probiotics.
• Biological therapies are indicated for non-responsive or high-risk patients.

Purpose of the Study:

• To review current and emerging biological treatments for inflammatory bowel diseases.
• To highlight the efficacy and limitations of anti-tumor necrosis factor α antibodies.
• To introduce newer biologic agents with more selective mechanisms of action.

Main Methods:

• Review of existing medical literature on inflammatory bowel disease treatments.
• Analysis of conventional and biological therapeutic options.
• Discussion of the mechanisms and clinical applications of various biologics.

Main Results:

• Anti-tumor necrosis factor α antibodies are effective but have limitations in long-term use due to loss of efficacy and adverse effects.
• Newer biologics, such as anti-integrin antibodies and interleukin 12/23 antibodies, offer more targeted approaches.
• These novel agents represent advancements in managing inflammatory bowel disease.

Conclusions:

• Biological treatments have significantly impacted the management of inflammatory bowel disease.
• Selective biologics provide promising alternatives with potentially improved safety and efficacy profiles.
• Continued research into novel therapeutic targets is crucial for advancing inflammatory bowel disease care.